0000950170-24-030484.txt : 20240313 0000950170-24-030484.hdr.sgml : 20240313 20240313060407 ACCESSION NUMBER: 0000950170-24-030484 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240308 FILED AS OF DATE: 20240313 DATE AS OF CHANGE: 20240313 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McNeill Jonathan CENTRAL INDEX KEY: 0001824673 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39509 FILM NUMBER: 24744501 MAIL ADDRESS: STREET 1: C/O DYNE THERAPEUTICS, INC. STREET 2: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dyne Therapeutics, Inc. CENTRAL INDEX KEY: 0001818794 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 364883909 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 786-8230 MAIL ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 4 1 ownership.xml 4 X0508 4 2024-03-08 0001818794 Dyne Therapeutics, Inc. DYN 0001824673 McNeill Jonathan 1560 TRAPELO ROAD WALTHAM MA 02451 false true false false Chief Business Officer true Common Stock 2024-03-08 4 M false 86159 5.54 A 227343 D Common Stock 2024-03-08 4 M false 3841 5.54 A 231184 D Common Stock 2024-03-08 4 S false 34663 25.46 D 196521 D Common Stock 2024-03-08 4 S false 54648 26.72 D 141873 D Common Stock 2024-03-08 4 S false 689 27.31 D 141184 D Common Stock 2024-03-11 4 M false 17825 5.54 A 159009 D Common Stock 2024-03-11 4 S false 17825 25.48 D 141184 D Common Stock 2024-03-11 4 S false 1776 25.71 D 139408 D Stock option (right to buy) 5.54 2024-03-08 4 M false 86159 0 D 2030-07-30 Common Stock 86159 12309 D Stock option (right to buy) 5.54 2024-03-08 4 M false 3841 0 D 2030-07-30 Common Stock 3841 17825 D Stock option (right to buy) 5.54 2024-03-11 4 M false 17825 0 D 2030-07-30 Common Stock 17825 0 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.25 to $26.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.25 to $27.19, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.27 to $27.39, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.14 to $26.09, inclusive. Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.67 to $25.81, inclusive. Includes 132,976 unvested RSUs. The option was granted on July 31, 2020. The shares underlying the option vest over four years in equal quarterly installments beginning on October 31, 2020. The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one ofitsproduct candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined thattheperformance condition had been achieved. /s/ Richard Scalzo, Attorney-in-Fact 2024-03-12